XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
A

miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/222 Cluster in More Favorable Prognosis, miR-15a & miR-16 in Bone Disease

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Aristea-Maria Papanota
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Aristea-Maria Papanota
16 views
January 12, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

19:39
Pfizer Hematology

Making the First Chance Count: Manuel

Feat. A. Ip

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Myeloma
15:54

MRD in Newly Diagnosed MM: MRI vs. PET/CT, RVD+/-ASCT, Dara+Len to R…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

E. Terpos

12 views
14:53

miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/22…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

A. Papanota

16 views
23:52

Decision Making in R/R MM: What Options to Consider for 1st Relapse …

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

A. Maiolino

43 views
16:34

Frontline MM Updates: What Are the Benefits of Long-Term, Continuous…

XIth Eurasian Hematology-Oncology Congress - EHOC 2020

M. Mateos

139 views